AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06523543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Second semester of pregnancy (Visit 2 - Week 20-24)
Description: Ultrasound examination (determination of chromosomal sex)
Study NCT06523543 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Third semester of pregnancy (Visit 3- Week 34)
Description: Ultrasound examination (determination of chromosomal sex) if this has not be done during the Visit 2 or if a new determination correcting the previous one is provided.
Study NCT05173233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Annuloplasty
Description: Under echocardiography guidance, the transcatheter tricuspid annuloplasty system precisely reaches the specified position in the tricuspid valve region via jugular vein and superior vena cava approach. The enlarged tricuspid annular tissue is clamped with the clamp cpart and anchor part to reduce the perimeter of tricuspid annulus, so that the area of tricuspid orifice that could not be coapted is reduced. It plays the purpose of minimally invasive treatment of tricuspid valve.
Study NCT06291740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous nebulization
Description: continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min
Study NCT06291740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent nebulization
Description: intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour
Study NCT06131216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-2022 Injection
Description: SHR-2022 Injection is administered by intravenous (IV) infusion
Study NCT05197205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swabbing
Description: A nasopharyngeal swab is collected during the consultation, with bacteriological analysis. No follow-up visit is required for this study
Study NCT05674318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-lactalbumin
Description: Oral assumption of two tabs/day containing Alpha-lactalbumin for 30 days
Study NCT06290804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: education
Description: Training program on Health Impacts of Sustainable Behaviors and Climate Change
Study NCT05167279 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS026/placebo
Description: Five dose groups (30 mg, 100 mg, 300 mg, 600 mg, and 1000 mg) will be set to receive an intravenous infusion of JS026/placebo on Day1, and two dose groups (300 mg JS026 + 1200 mg JS016, and 600 mg JS026+ 1200 mg JS016) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
Study NCT05167279 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: JS016/placebo
Description: Two dose groups (300 mg + 1200 mg, and 600 mg + 1200 mg) will be set to receive an intravenous infusion of JS026/placebo + JS016/placebo on Day1. The investigational product and placebo will be distributed in each dose group in a ratio of 3:1.
Study NCT05897528 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Difference in outcomes in patients with COVID-19 diagnosis and diabetes mellitus groups
Study NCT05542394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: water soluble version of turmeric extract standardized to 10% curcuminoids~.
Study NCT05542394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: water soluble version of turmeric extract standardized to 10% curcuminoids~.
Study NCT05542394 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: water soluble version of turmeric extract standardized to 10% curcuminoids~.
Study NCT06379568 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06368882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-Interferon α
Description: Peg IFN-α injection was subcutaneously injected 180 μg weekly on the first day of the first week, and NAs was administered daily according to the standard dosage of each drug. For example, HBsAg sero-conversion is achieved within 48 weeks of treatment, Peg IFNα combined with NAs or PEG-IFNα monotherapy was continued for 12 weeks, with a maximum of 96 weeks, and follow-up up to 240 weeks after treatment. If HBsAg negative sero-conversion is not achieved within 48 weeks of treatment, the maximum duration of PEG-IFNα is not more than 96 weeks. If Peg IFNα combined NAs regimen is used, NAs can be continued until the drug can be ended (if HBsAg negative conversion is achieved, NAs should be ended after consolidation therapy not less than 24 weeks; if HBsAg negative conversion is not achieved, NAS should be continued), followed up to 240 weeks after treatment.
Study NCT05572372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: The aim of the intervention was to increase psychological flexibility. Therapeutic methods focused on values clarification, cognitive defusion, self-as-context, acceptance, commited action and flexible attention to present moment.
Study NCT05786612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain® Silicone
Description: Wound care dressing
Study NCT05786612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Border with Aquacel Extra Hydrofiber
Description: Wound care dressing
Study NCT05385224 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PillSense
Description: The PillSense System is intended to detect the presence of blood in the stomach for the evaluation of upper gastrointestinal bleeding.
Study NCT05277350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SNIPR001
Description: SNIPR001 is a live biotherapeutic product consisting of genetically modified bacteriophages specifically targeting Escherichia coli
Study NCT05277350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05075044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: three doses of inactivated COVID-19 vaccine
Study NCT06509672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Plyometric and Endurance Training
Description: this include Combined Plyometric and Endurance Training for 12 weeks
Study NCT06509672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric Training
Description: this include Plyometric Training for 12 weeks
Study NCT06509672 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endurance training
Description: this include Endurance Training for 12 weeks
Study NCT04482244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Liquid taken orally
Study NCT04482244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid taken orally
Study NCT05078749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training group
Description: A regular advanced exercise program will be given and followed.
Study NCT05078749 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control training group
Description: Basic exercises will be given at the beginning and will do the same exercises
Study NCT05917548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Teledentistry oral health promotion
Description: Educational videos specially designed and validated for elderly (duration 4 to 6 minutes each one)
Study NCT05917548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-Face oral health promotion
Description: Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
Study NCT05917548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-Face oral health promotion
Description: Standardized PowerPoint presentation of 15 minutes about the most common or dangerous oral diseases (dental caries, periodontal disease and oral cancer), and toothbrushing and flossing practice in dental models
Study NCT06259513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omission of SLNB in SentiOMIT or omission of ALND in SentiMACRO
Description: Omission of SLNB in cT1-2N0 or Omission of ALND in patients with \</= 2 macrometastasis in SLNB
Study NCT05233384 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood test
Description: For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation).
Study NCT06009809 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transesophageal echocardiogram
Description: To measure mean blood velocity at the level of the right renal and superior mesenteric artery
Study NCT00000774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rgp120/HIV-1MN
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
Study NCT00000774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rgp120/HIV-1 SF-2
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
Study NCT00000774 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo version of rgp120/HIV-1MN
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
Study NCT00000774 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo version of rgp120/HIV-1SF2
Description: Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
Study NCT06020209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Computed Tomography
Description: A comprehensive CCT protocol will be performed in the post-acute phase of STEMI. Specifically, the CCT protocol will include a pre-contrast scan and an angiographic scan ( also set up to assess ventricular volume and function) followed by late contrast enhancement scan.
Study NCT06020209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance
Description: A comprehensive CMR protocol will be performed in the post-acute phase of STEMI. Specifically, the CMR protocol is designed for morpho-functional analysis and tissue characterisation (including assessment of late gadolinium enhancement and mapping). CMR will be considered the gold standard.
Study NCT06330220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection [Eylea]
Description: intravitreal injection
Study NCT04902729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Patient is given carbetocin (80mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
Study NCT04902729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Patient is given oxytocin (1IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby, followed by infusion 80 mU/min (40 IU in 1L given at a rate of 120 mL/h).
Study NCT04748172 — intervention group
Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 virus vaccines
Description: mRNA SARS-CoV-2 virus vaccines ( By Pfizer or Moderna)
Study NCT04748172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AMH sampling
Description: Blood sample for AMH on recruitment and after three months
Study NCT04748172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anti Covid-19 antibody levels (Serology)
Description: Blood sample for IgG against S1 protein after three months
Study NCT04946552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PET Scan
Description: Participants will come to the PET Center to undergo the whole body \[11C\]MRB PET scan. An intravenous bolus dose of MRB (\~20mCi) will be injected by an infusion pump. PET data will be acquired dynamically for 120 min using the Siemens mCT-X whole-body PET/CT scanner using continuous bed motion to image multiple PET bed acquisitions from the top of the head to the lower abdominal region.
Study NCT04946552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mixed Meal Test
Description: High Carbohydrate Mixed Meal Test (MMT): participants will be studied after a 10-hour overnight fast. A nurse will insert an intravenous (IV) catheter and subjects will ingest a liquid meal (65% carbohydrate, 20% fat, and 15% protein, corresponding to 40% of daily energy expenditure, in \~16 ounces) to be prepared by the Hospital Research Unit Metabolic Kitchen. Blood samples will be collected at -10, 0, 15, 30, 60, 90, and 120 min) for measurement of glucose, insulin and C-peptide concentrations. Plasma samples will be drawn at baseline and throughout the MMT for measurement of additional hormones (such as thyroid hormones, and catecholamines) and free fatty acids (FFA) levels.
Study NCT04946552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Muscle sympathetic nerve activity (MSNA)
Description: Recording of multiunit postganglionic muscle sympathetic nerve activity (MSNA) will be made from the common peroneal nerve as it winds around the fibular head with the subject in the supine position with the subject's thigh comfortably supported. This procedure requires to first trace the course of the nerve using small electrical stimuli applied to the surface of the skin over the nerve or use of ultrasound to visually assist.
Study NCT04946552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral Glucose Tolerance Test
Description: Following a 10-hour overnight fast, a nurse will insert an intravenous (IV) catheter. Subsequently, subjects will ingest 7.5 oz of Glucola, which contains 75 g of dextrose in orange flavored water. Blood samples will be taken at -15, 0, 10, 20, 30, 60, 90 and 120 minutes (after glucola ingestion) for the measurement of plasma glucose, insulin, and C-peptide concentrations, and calculation of measurements of insulin sensitivity index (Matsuda Index). Approximately 40 mL of blood will be drawn at this visit.
Study NCT04946552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition, Percent Body Fat & Percent Body Water (Tanita scale)
Description: will be assessed using bioelectrical impedance analysis Tanita® scale; which is a special multi frequency segmental body composition analyzer that delivers a very mild electrical current that allows measurement of fat mass, percent body fat, fat free mass, total body water, and percent body water. This test will be performed at screening visit.
Study NCT04946552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT Scan
Description: A CT scan will be performed for attenuation correction and to help delineate the BAT and other regions of interest (ROIs). Images will be reconstructed with an ordered subset expectation maximization algorithm using point spread function correction and time-of-flight information. To delineate fat (WAT, BAT) and skeletal muscle regions of interests (ROIs), CT images are first resliced to match the resolution and location of PET images. As performed in previous studies 2, a supraclavicular ROI is first manually drawn on the CT images. Within that area, the fat ROI is segmented using the CT images and an intensity window from -200 to -50 HU. Subsequently the fat ROI is segmented into WAT and BAT ROIs by using the 11C-MRB PET images: Standardized Uptake Value (SUV) ≥ 1.25 for BAT, SUV \< 1.25 for WAT.
Study NCT04946552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition, Percent Body Fat & Percent Body Water (DXA Scan)
Description: For better accuracy, measurement of percent fat and percent body water will be obtained with whole body Dual X-Ray Absorptiometry (DXA) scan (Hologic®) on screening-OGTT visit. The scanner arm will move over the participant's body from feet to head. The machine uses a small amount of radiation (one tenth of the amount of radiation from a chest x-ray) to measure body fat, muscle and bone density.
Study NCT05011097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y150
Description: Subjects will receive an intravenous infusion of Y150 in a dose escalation once a week for a 28-day treatment cycle until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.
Study NCT04930614 — intervention group
Intervention type: OTHER
Intervention: Survey on socio-demographic variables and healthcare-seeking, sexual and drug-using behaviour
Description: Digital survey to estimate the associated risk factors for HIV infections in transgender and non-binary people in Flanders and Brussels (Belgium)
Study NCT05845840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-297
Description: Escalating doses of BRII-297 will be given in different cohorts i.e., Cohorts 1 through 6
Study NCT05845840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Escalating doses of placebo will be given in different cohorts i.e., Cohorts 1 through 6
Study NCT05140616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: After screening according to inclusion and exclusion criteria, patients meeting the criteria were enrolled. Treatment regimen: Chidamide 15mg biw po, lasted for 8 weeks. Pretransplant use of Chidamide for reasons other than cGVHD, such as for the treatment of leukemia or lymphoma, was permitted.All patients received systemic corticosteroid therapy for cGVHD prior to and during the study; concomitant use of other immunosuppressive therapies was also permitted, however, pre-existing corticosteroid and immunosuppressant doses must have been stable for 14 days before initiating Chidamide. Doses of concomitant corticosteroids and immunosuppressants could be tapered during the study as clinically indicated.
Study NCT04760379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
Study NCT04760379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vibration therapy
Description: Focal muscle vibrator (120 Hz) for 10 minutes on paraspinal muscles. Bridging, Stretching exercises (quadratus lumborum, erector spinae) McKenzie exercises and TENS (10 mins).
Study NCT05679180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: micropulse laser
Description: treatment with confluent spots over the area of focal leak on the earliest phase of fundus fluorescein angiography on Navilas® system using 5% duty cycle with 100 micron spot size with 200 ms envelope. Thirty percent of threshold laser burn power was used.
Study NCT06271564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnetite ZnO Composite Nanoparticles
Description: Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell
Study NCT06271564 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Placebo Gel
Description: Topical placebo gel containing water, glycerin and Hydroxypropyl methylcellulose will be applied 3 times daily for 6 weeks as a positive control group
Study NCT04719468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance with ballet elements
Description: Ballet-based dance sessions will be delivered by trained artists within the English National Ballet group in a professional dance space/ delivered remotely, COVID-19 permitting.
Study NCT04810559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test
Description: OraQuick ADVANCE® HIV-1/2 Rapid Antibody Test in oral fluid and fingerstick blood conducted by untrained healthcare providers compared to laboratory 4th generation Ag/Ab EIA results performed on venous blood.
Study NCT04811118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for Injection (Albumin-bound)
Description: Docetaxel for Injection (Albumin-bound) by intravenous infusion
Study NCT04811118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Description: Taxotere
Study NCT05730517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CP5HA
Description: Test group 1 will receive investigational product 1 containing collagen (5 g/ 15 mL), hyaluronic acid (30 mg/ 15 mL) and vitamin C (80 mg/ 15 mL); continuous administration of investigational product for 16 weeks.
Study NCT05730517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo syrup
Description: Placebo group will receive placebo syrup without active ingredients. (daily dose 25 mL: collagen: 0 mg, MSM: 0 mg, vitamin C: 0 mg; continous administration of placebo product for 16 weeks.